H.C. Wainwright Downgrades Aravive Inc. (ARAV) to Neutral, 'company in a precarious position'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to H.C. Wainwright Downgrades Aravive Inc. (ARAV) to Neutral, 'company in a precarious position'
August 3, 2023 4:32 AM EDT
William Blair analyst Andy Hsieh downgraded Aravive Inc. (NASDAQ: ARAV) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Aravive Inc. click here. For more ratings news on Aravive Inc. click here.
Shares of Aravive Inc. closed at $1.28 yesterday.
...
More
August 3, 2023 2:27 AM EDT
(Updated - August 3, 2023 4:41 AM EDT)
BTIG analyst Justin Zelin downgraded Aravive Inc. (NASDAQ: ARAV) from Buy to Neutral.
The analyst comments "Today AMC, ARAV reported that the pivotal AXLerate-OC trial in platinum resistant ovarian cancer did not meet the... More
August 2, 2023 4:23 PM EDT
Aravive Inc. (NASDAQ: ARAV) to Resume Trading at 4:35 p.m. After Announcing Trial Fails
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian CancerTrial did not meet primary endpoint of progression-free survivalCash at the end...
More
August 2, 2023 4:01 PM EDT
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment. The trial did not show any difference between the two arms in the overall population (which included patients previously treated with bevacizumab). The Company will continue to evaluate the complete dataset and determine next steps in the development of... More
